Showing results (61-70 of 97) with videos related to
Sort By:
Pageof 10
Cancers|April 3, 2021
Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic CancerBrittany J Poelaert, Shelby M Knoche, Alaina C Larson, et al.Nature Cancer|March 27, 2023
Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanismZhenyi Su, Ning Kon, Jingjie Yi, et al.Cancer Cell|November 9, 2010
Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancerFerdinandos Skoulidis, Liam D Cassidy, Venkat Pisupati, et al.Gut|May 13, 2020
Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppressionRyota Takahashi, Marina Macchini, Masaki Sunagawa, et al.Theranostics|April 16, 2020
Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivoAlireza Nabavizadeh, Thomas Payen, Alina C Iuga, et al.Carcinogenesis|May 6, 2015
Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanismFilip Bednar, Heather K Schofield, Meredith A Collins, et al.Nature Biomedical Engineering|March 29, 2022
High-speed light-sheet microscopy for the in-situ acquisition of volumetric histological images of living tissueKripa B Patel, Wenxuan Liang, Malte J Casper, et al.Nature Communications|November 16, 2019
Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancerKatherine A Michaelis, Mason A Norgard, Xinxia Zhu, et al.Nature Communications|October 17, 2019
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancerKatherine A Michaelis, Mason A Norgard, Xinxia Zhu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2015
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphomaSalvia Jain, Xavier Jirau-Serrano, Kelly M Zullo, et al.Pageof 10